Lung Cancer Trials Ask AI to find trials
Approved For MarketingNot applicableNCT03906331
Official study title

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Study summary

Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedSelpercatinib

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · RET

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 17, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Approved For Marketing

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Expanded Access

Where is it offered?64 U.S. locations

Locations may change over time.

Who runs it?Eli Lilly and Company

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Expanded Access
Phase
Not applicable
Sponsor
Eli Lilly and Company
Interventions being studied
Drug: Selpercatinib
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Biomarkers
RET→
Treatment approach
Targeted therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib
  • Have progressed or are intolerant to standard therapy, or no standard therapy option exists, or in the opinion of the investigator, are unlikely to derive significant clinical benefit from standard therapy
  • Have adequate organ function
Reasons someone may not be able to joinExclusion criteria
  • Currently enrolled in an ongoing clinical study of selpercatinib or another RET inhibitor
  • Clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to study treatment; ongoing cardiomyopathy; or current prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) interval greater than 470 milliseconds

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Cancer Treatment Centers of AmericaGoodyear, Arizona
  • Mayo Clinic of ScottsdaleScottsdale, Arizona
  • City of Hope National Medical CenterDuarte, California
  • UCLA Medical CenterLos Angeles, California
  • Kaiser PermanenteOakland, California
  • Irvine Medical CenterOrange, California
  • University of California - San DiegoSan Diego, California
  • Univ of California San FranciscoSan Francisco, California
  • Kaiser PermanenteSanta Clara, California
  • Kaiser Permanente Medical CenterVallejo, California
  • Memorial Cancer InstituteHollywood, Florida
  • Mayo Clinic in FloridaJacksonville, Florida

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 17, 2025. Always confirm current availability with the study team.

View original record ↗